Small-molecule photothermal agents(PTAs)with intense second near-infrared(NIR-Ⅱ,1,000 to 1,700 nm)absorption and high photothermal conversion efficiencies(PCEs)are promising candidates for treating deep-seated tumors...Small-molecule photothermal agents(PTAs)with intense second near-infrared(NIR-Ⅱ,1,000 to 1,700 nm)absorption and high photothermal conversion efficiencies(PCEs)are promising candidates for treating deep-seated tumors such as osteosarcoma.To date,the development of small-molecule NIR-Ⅱ PTAs has largely relied on fabricating donor–acceptor–donor(D–A–D/D′)structures and limited success has been achieved.Herein,through acceptor engineering,a donor–acceptor–acceptor(D–A–A′)-structured NIR-Ⅱ aza-boron-dipyrromethene(aza-BODIPY)PTA(SW8)was readily developed for the 1,064-nm laser-mediated phototheranostic treatment of osteosarcoma.Changing the donor groups to acceptor groups produced remarkable red-shifts of absorption maximums from first near-infrared(NIR-Ⅰ)regions(~808 nm)to NIR-Ⅱ ones(~1,064 nm)for aza-BODIPYs(SW1 to SW8).Furthermore,SW8 self-assembled into nanoparticles(SW8@NPs)with intense NIR-Ⅱ absorption and an ultrahigh PCE(75%,1,064 nm).This ultrahigh PCE primarily originated from an additional nonradiative decay pathway,which showed a 100-fold enhanced decay rate compared to that shown by conventional pathways such as internal conversion and vibrational relaxation.Eventually,SW8@NPs performed highly efficient 1,064-nm laser-mediated NIR-Ⅱ photothermal therapy of osteosarcoma via concurrent apoptosis and pyroptosis.This work not only illustrates a remote approach for treating deep-seated tumors with high spatiotemporal control but also provides a new strategy for building high-performance small-molecule NIR-Ⅱ PTAs.展开更多
基金the National Key R&D Program of China(2020YFA0709900)the National Natural Science Foundation of China(62288102,22077101,62175201,and 22004099)+3 种基金the Joint Research Funds of Department of Science&Technology of Shaanxi Province and North-western Polytechnical University(2020GXLH-Z-008,2020GXLH-Z-021 and 2020GXLH-Z-023)the Open Project Program of Wuhan National Laboratory for Optoelectronics(Nos.2020WNLOKF023 and 2022WNLOKF009)The Natural Science Foundation of Ningbo(202003N4049 and 202003N4065)the Natural Science Foundation of Shaanxi Province(2022JM-130).
文摘Small-molecule photothermal agents(PTAs)with intense second near-infrared(NIR-Ⅱ,1,000 to 1,700 nm)absorption and high photothermal conversion efficiencies(PCEs)are promising candidates for treating deep-seated tumors such as osteosarcoma.To date,the development of small-molecule NIR-Ⅱ PTAs has largely relied on fabricating donor–acceptor–donor(D–A–D/D′)structures and limited success has been achieved.Herein,through acceptor engineering,a donor–acceptor–acceptor(D–A–A′)-structured NIR-Ⅱ aza-boron-dipyrromethene(aza-BODIPY)PTA(SW8)was readily developed for the 1,064-nm laser-mediated phototheranostic treatment of osteosarcoma.Changing the donor groups to acceptor groups produced remarkable red-shifts of absorption maximums from first near-infrared(NIR-Ⅰ)regions(~808 nm)to NIR-Ⅱ ones(~1,064 nm)for aza-BODIPYs(SW1 to SW8).Furthermore,SW8 self-assembled into nanoparticles(SW8@NPs)with intense NIR-Ⅱ absorption and an ultrahigh PCE(75%,1,064 nm).This ultrahigh PCE primarily originated from an additional nonradiative decay pathway,which showed a 100-fold enhanced decay rate compared to that shown by conventional pathways such as internal conversion and vibrational relaxation.Eventually,SW8@NPs performed highly efficient 1,064-nm laser-mediated NIR-Ⅱ photothermal therapy of osteosarcoma via concurrent apoptosis and pyroptosis.This work not only illustrates a remote approach for treating deep-seated tumors with high spatiotemporal control but also provides a new strategy for building high-performance small-molecule NIR-Ⅱ PTAs.
